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December 13/20, 2011:2696–702myocardium must have undergone enough damage to exceed its
ability to compensate. The authors conclude that both tissue
velocity and strain imaging could detect pre-clinical changes in
cardiac function, before EF decreases, in patients receiving adju-
vant trastuzumab. Notably, they found no change in plasma
biomarkers (troponin T, C-reactive protein, and brain natriuretic
peptide); troponin I (TnI) was not evaluated.
Recently, Cardinale et al. (2) identified a subgroup of
rastuzumab-treated patients who exhibited elevations in serum
nI, and who were more likely to develop cardiotoxicity and less
ikely to recover, even when treated for cardiac dysfunction: prior
se of anthracyclines was a significant risk factor; cumulative
nthracycline dose was significantly higher. Elevation of TnI,
bserved exclusively in patients with prior anthracycline exposure,
as also found in 7 patients prior to trastuzumab therapy, despite
ormal EF, suggesting ongoing anthracycline-mediated myocyte
amage that would have otherwise gone unrecognized (3). Thus, it
ppeared that TnI leak was not a “pure” marker of trastuzumab
ardiotoxicity. Rather, trastuzumab exerted a modulating effect on
he vulnerable myocyte, previously damaged by anthracyclines.
Also, in line with our preliminary data on speckle tracking
etection of early left ventricular (LV) dysfunction in mice
reated with anti-ErbB2 agents, with increased cardiac fibrosis
videnced by histology (4,5), Fallah-Rad et al. (1) show
vidence of subepicardial linear delayed enhancement in the
ateral wall of the LV in trastuzumab cardiomyopathy, with a
rogressive decline in LVEF, despite discontinuation of tras-
uzumab and initiation of heart failure therapy, suggesting that
he paradigm of reversibility of trastuzumab-induced cardiomy-
pathy needs to be re-evaluated.
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Reply
Breast cancer and cardiovascular disease are major public health
concerns worldwide. The 2 diseases are intricately linked as
treatment with established chemotherapeutic agents and monoclo-
nal antibodies, including doxorubicin and trastuzumab, may lead
to breast cancer remission, but alternatively, may also lead to
significant cardiotoxicity. In the emerging field of cardio-oncology,
early indices of left ventricular (LV) systolic dysfunction would be
useful for addressing the cardiac safety profile of trastuzumab,
potentially avoiding the detrimental effects of heart failure.
We recently evaluated the utility of cardiac biomarkers, tissue
Doppler imaging (TDI), and cardiac magnetic resonance imaging
(CMR) for predicting early LV systolic dysfunction in HER-2–
positive breast cancer patients treated with trastuzumab in the
adjuvant setting (1). Of the 10 (25%) women who developed
trastuzumab-induced cardiotoxicity (TIC), cardiac biomarkers includ-
ing troponin (Tn)T, C-reactive protein, and brain natriuretic peptide
did not predict early LV systolic dysfunction (1). As suggested by
Tocchetti et al. (2), our findings contrast with a previous study in
which troponin I was able to identify a subset of women at high risk
of doxorubicin- and trastuzumab-mediated cardiac dysfunction prior
to a decrease in left ventricular ejection fraction (LVEF). One
potential explanation for the difference is the frequent sampling of
TnI, both before and after each trastuzumab cycle, as in the study by
Cardinale et al. (3), which provides a more accurate assessment of
biomarker levels in this patient population.
As compared with cardiac biomarkers, echocardiography using
TDI was sensitive in detecting pre-clinical changes in LV systolic
dysfunction. We agree with Dr. Tocchetti and colleagues that a
number of both basic science and clinical studies have recently
confirmed the utility of TDI for the early identification of LV
systolic dysfunction in breast cancer patients receiving doxorubicin
and trastuzumab (2,4–7). Although both TDI and strain imaging
were able to detect pre-clinical changes in LV systolic dysfunction
in breast cancer patients, the decision to either continue or
withhold trastuzumab therapy requires further study.
CMR using delayed enhancement (DE) is the gold standard for
the noninvasive assessment of cardiac volumes, systolic function,
and degree of fibrosis. To address the comments by Drs. Was-
smuth and Schulz-Menger, all 10 women in our study had normal
CMR studies at baseline, with no evidence of DE of the LV
myocardium, prior to initiation of doxorubicin and trastuzumab.
At 1-year follow-up, there was mid-myocardial DE of the lateral
wall of the LV in each of the 10 women with TIC, with no
evidence of myocardial edema on T2 imaging (1). We agree with
Drs. Wassmuth and Schulz-Menger that confirmatory studies by
other groups are required and likely forthcoming. As there was no
evidence of subendocardial DE in our patient population, one can
assume that there was no significant obstructive coronary artery
disease as questioned by Dr. Ntim. Finally, in response to Ntim,
there was no use of antiplatelet or statin therapy in our patient
cohort. The identification of DE of the LV myocardium in breast
cancer patients challenges the paradigm of whether trastuzumab-
mediated cardiac dysfunction is truly reversible in all cases.
The anticipated goal of cardio-oncologists should be to continue to
improve overall morbidity and mortality in breast cancer patients
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December 13/20, 2011:2696–702treated with doxorubicin and trastuzumab, while at the same time,
preventing any detrimental side effects on cardiac health.
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Cardiovascular Risk Assessment of
Liver Transplantation Candidates
We read with great interest the report by Raval et al. (1) on
cardiovascular risk assessment of candidates for liver transplanta-tion (LT) and would like to congratulate the investigators on a
comprehensive and thorough review.
We disagree, however, with a comment made in the section on
heart failure and cardiomyopathy and the evidence provided in the
report. The investigators, quite rightly, recommend that all pa-
tients undergo pre-operative transthoracic echocardiography, a
practice routinely undertaken at LT centers. They then state that
patients with left ventricular ejection fractions as low as 10% have
successfully undergone LT after aggressive medical management,
citing a Canadian case series (2). We believe this deserves further
analysis. The publication describes 4 patients with end-stage
hypertrophic, dilative, and ischemic cardiomyopathy who under-
went combined cardiac transplantation and LT on cardiopulmo-
nary bypass. All patients were highly symptomatic, with New York
Heart Association functional class III or IV heart failure, and 3 had
congestive cirrhosis due to right ventricular failure. It appears as if
the primary indication for transplantation was cardiac, but heart
transplantation alone was not possible, because of end-stage liver
disease. We believe that the term “aggressive medical manage-
ment” is misleading in this context and does not appropriately
describe the complexity of the procedures performed. We strongly
believe that severe and symptomatic heart failure is an absolute
contraindication for LT, unless a combined heart and liver
transplantation procedure is considered.
In the section on recommendations for assessment, the role of
cardiopulmonary exercise testing, in particular the assessment of
aerobic capacity, was not commented on. The most sensitive index
of aerobic capacity is oxygen consumption at peak exercise (peak
VO2). Evaluation of peak VO2 is increasingly used at LT centers as
part of the routine assessment. Dharancy et al. (3) demonstrated
that a peak VO2 of 60% was associated with reduced 1-year
urvival in patients listed for LT. The predictive ability of peak
O2 was more evident in patients with Model for End-Stage Liver
isease scores 17.
In summary, severe left ventricular failure remains in our view
n absolute contraindication for LT despite aggressive medical
anagement. Dynamic cardiopulmonary testing and assessment of
erobic capacity provides important prognostic information and
hould be considered in all patients undergoing elective LT
ssessment.
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